Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

Adults with obstructive sleep apnea (OSA) are at increased risk for vertigo and vestibular dysfunction, relative to those without OSA.

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions associated with excess morbidity and mortality – – Obstructive ...

“Today’s approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, M.D., director of the Division of Pulmonology, Allergy, and Critical ...